Nektar Therapeutics | NKTR - 营业费用



金融业
股票价格
USD
资产
USD 763.27M
现金及等价物
USD 149.58M
销售成本
USD 4.44M
流动资产
USD 589.04M
流动负债
USD 57.71M
债务
USD 0
股息收益率
0
EBIT
USD -38.26M
EBITDA
USD -38.9M
员工
137
EPS每股收益
USD -1.78
股本和储备
USD 576.22M
销售毛利
USD 10.86M
债务利息支出
USD 7.94M
利息收入
USD -0.18
贷款资金
USD 60.27M
市值
USD 10.91B
净收入
USD -44.9M
营业费用
USD 49.12M
营业利润
USD -38.26M
普通股股本
USD 29.47M
税前利润
USD -43.09M
销售收入
USD 10.86M
销售和管理费用
USD 11.87M
股票
USD 14.46M
贸易债权人
USD 10.03M
应收帐款人
USD 3.6M


营业费用 更改 日
Agios Pharmaceuticals USD 130.77M 10.77M 2026-03
ALKERMES USD 1.81B 57.02M 2026-06
Alterity Therapeutics Limited AUD 8.67M 893.38K 2025-12
Amgen USD 11.69B 6.9B 2026-06
Baxter International USD 2.68B 3.36B 2026-06
BioCryst Pharmaceuticals USD 119.78M 673.63M 2026-06
Biogen USD 2.98B 1.02B 2026-06
Bristol-Myers Squibb USD 22.32B 2.25B 2026-06
Cara Therapeutics USD 7.05M 1.11M 2026-03
Cipla INR 62.31B 3.04B 2026-06
Dr.Reddys Laboratories INR 77.75B 3.17B 2026-06
Eisai JPY 209.6B 6.14B 2026-06
Eli Lilly USD 10.52B 496M 2026-06
Exelixis USD 380.28M 20.8M 2026-06
Gilead Sciences USD 3.95B 19.57B 2026-06
GlaxoSmithKline GBP 5.8B 468M 2026-06
Grifols EUR 1.99B 217.4M 2025-12
Halozyme Therapeutics USD 193.34M 1.15M 2026-06
Incyte USD 973.64M 4.65B 2026-06
Ionis Pharmaceuticals USD 370.24M 6.24M 2026-06
Ironwood Pharmaceuticals USD 57.33M 8.63M 2024-12
Karyopharm Therapeutics USD 61.83M 9.9M 2026-03
MacroGenics USD 42.87M 21.68M 2026-06
Merck USD 15.77B 2.4B 2026-06
Nektar Therapeutics USD 49.12M 8.22M 2026-03
Neurocrine Biosciences USD 739.1M 139.2M 2026-06
Novartis USD 10.2B 912M 2026-06
Pfizer USD 85.19B 4.91B 2026-06
Roche Holding CHF 18.9B 2.12B 2026-06
Sarepta Therapeutics USD 387.96M 15.59M 2026-06
Takeda JPY 1.02T 89.68B 2026-06
Teva Pharmaceutical Industries USD 3.92B 691M 2026-06
Xencor USD 87.82M 5.44M 2026-06